歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

未开盘 02-01 16:08:35

4.270

+0.090

+2.15%

最高4.300	最低4.050	成交量202.60万
今开4.160	昨收4.180	日振幅5.98%
总市值46.42亿	流通市值46.42亿	总股本10.87亿
成交额851.56万	换手率0.19%	流通股本10.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":4.27,"timestamp":1675238915012,"preClose":4.18,"halted":0,"volume":2026000,"delay":0,"floatShares":1087134000,"shares":1087134000,"eps":-0.21068706,"marketStatus":"未开盘","marketStatusCode":0,"change":0.09,"latestTime":"02-01 16:08:35","open":4.16,"high":4.3,"low":4.05,"amount":8515620,"amplitude":0.059809,"askPrice":4.27,"askSize":6000,"bidPrice":4.25,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.18753586108997936,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1675301400000},"adr":0,"listingDate":1533052800000,"adjPreClose":4.18,"volumeRatio":0.5972525205110674,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"2308277399","title":"港股公告掘金 | 这公司用于治疗高血脂的ANGPTL3信使RNA小干扰RNA药物临床试验获国药监受理!此外，这公司的抗新冠口服药原料药与制剂，委托一间港股公司生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2308277399","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2308277399?lang=zh_CN&edition=full","pubTime":"2023-02-01 08:17","pubTimestamp":1675210670,"startTime":"0","endTime":"0","summary":"点评：JS401是该公司与合作伙伴润佳上海共同研发的一种“ANGPTL3”信使RNA的小干扰RNA药物，拟主要用于高脂血症等治疗。此外，君实生物另一则公告：公司控股子公司上海旺实生物医药科技有限公司与浙江“华海药业”签署了《产品委托生产及供货协议》，旺实生物授权华海药业生产和供应 VV116 的原料药，同时委托华海药业生产 VV116 的制剂。目前全球尚无治疗呼吸道合胞病毒感染的有效药物，治疗呼吸道合胞病毒感染仍有巨大的未满足的医疗需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/869467.html","is_publish_highlight":false},{"id":"2307797335","title":"歌礼制药-B(01672)：美国食药监局批准开展ASC10治疗呼吸道合胞病毒(RSV)感染IIa期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2307797335","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2307797335?lang=zh_CN&edition=full","pubTime":"2023-01-31 17:35","pubTimestamp":1675157713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，美国食品药品监督管理局已批准开展ASC10治疗呼吸道合胞病毒感染IIa期临床试验。ASC10和衍生物用于治疗新型冠状病毒、猴痘病毒及呼吸道合胞病毒等多种病毒感染的化合物专利及其用途专利已获美国专利与商标局授权。据估计，在65岁以上的美国成年人中，呼吸道合胞病毒感染每年导致约1.4万人死亡。目前全球尚无治疗呼吸道合胞病毒感染的有效药物，治疗呼吸道合胞病毒感染仍有巨大的未满足的医疗需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/869097.html","is_publish_highlight":false},{"id":"2306448012","title":"港股公告掘金 | 这公司猴痘适应症新药临床试验获得国药监批准!该药此前曾收到美国专利与商标局(USPTO)的授权公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2306448012","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2306448012?lang=zh_CN&edition=full","pubTime":"2023-01-27 08:20","pubTimestamp":1674778801,"startTime":"0","endTime":"0","summary":"猴痘病毒属于正痘病毒属病毒，可导致与天花症状相似的疾病。据世界卫生组织统计，截至2023年1月25日，全球已有超过85,106例确诊病例，猴痘病毒已在110个国家传播。ASC10和衍生物用于治疗新型冠状病毒、猴痘病毒及人呼吸道合胞病毒等多种病毒感染的化合物专利及其用途专利申请已收到美国专利与商标局的授权公告通知书。歌礼是首个获得美国专利与商标局授予自主研发口服病毒聚合酶抑制剂和衍生物专利的中国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/866786.html","is_publish_highlight":false},{"id":"2306107694","title":"港股1月27日早报：四环医药产品进入国家医保 歌礼制药猴痘药临床获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2306107694","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2306107694?lang=zh_CN&edition=full","pubTime":"2023-01-27 07:47","pubTimestamp":1674776840,"startTime":"0","endTime":"0","summary":"兔年春节前4天，境内酒店预订量已超越2019年同期。境内长途游订单量同比增长超500%。","market":"us","thumbnail":"https://img.cls.cn/images/20230127/sGuD9v21qb.jpg@!thumb_flash","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20230127/sGuD9v21qb.jpg@!thumb_flash"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://m.cls.cn/depth/1248864","is_publish_highlight":false},{"id":"2306282493","title":"财联社1月26日电，歌礼制药-B（01672.HK）公告，中国国家药品监督管理局已批准ASC10猴痘适应症新药临床试验（IND）申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2306282493","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2306282493?lang=zh_CN&edition=full","pubTime":"2023-01-26 20:55","pubTimestamp":1674737720,"startTime":"0","endTime":"0","summary":"财联社1月26日电，歌礼制药-B(01672.HK)公告，中国国家药品监督管理局已批准ASC10猴痘适应症新药临床试验(IND)申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301262146128253ddce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301262146128253ddce&s=b","is_publish_highlight":false},{"id":"2304505007","title":"歌礼制药-B盘中异动 大幅跳水5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2304505007","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2304505007?lang=zh_CN&edition=full","pubTime":"2023-01-18 13:36","pubTimestamp":1674020190,"startTime":"0","endTime":"0","summary":"2023年01月18日下午盘13时36分，歌礼制药-B股票出现异动，股价大幅跳水5.15%。截至发稿，该股报4.401港元/股，成交量228.7万股，换手率0.21%，振幅5.17%。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，和誉-B、3D MEDICINES-B、康诺亚-B涨幅较大，振幅较大的相关个股有3D MEDICINES-B、永泰生物-B、康诺亚-B，振幅分别为15.21%、10.39%、9.97%。消息层面，截至13时36分，歌礼制药-B股票正面舆情新闻比例46.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230118133630846d3162&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230118133630846d3162&s=b","is_publish_highlight":false},{"id":"2304554052","title":"歌礼制药-B(01672)与先声药业(02096)附属签订利托那韦片供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2304554052","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2304554052?lang=zh_CN&edition=full","pubTime":"2023-01-17 08:19","pubTimestamp":1673914759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，公司全资附属公司歌礼药业(浙江)有限公司与先声药业(02096)附属公司海南先声药业有限公司签订利托那韦片供应协议。利托那韦片是针对病毒蛋白酶的多种口服抗病毒药物的药代动力学增强剂。目前，歌礼拥有中国唯一通过生物等效性研究获批上市的利托那韦口服片。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/862980.html","is_publish_highlight":false},{"id":"2304554029","title":"歌礼制药：与先声签订利托那韦片供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2304554029","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2304554029?lang=zh_CN&edition=full","pubTime":"2023-01-17 08:18","pubTimestamp":1673914680,"startTime":"0","endTime":"0","summary":"【歌礼制药：与先声签订利托那韦片供应协议】歌礼制药公告，全资附属公司与先声药业集团有限公司附属公司海南先声药业有限公司签订利托那韦片供应协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301170818198250b4ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301170818198250b4ef&s=b","is_publish_highlight":false},{"id":"2303795233","title":"歌礼制药-B(01672.HK)早盘再涨近6%，截至发稿，涨5.4%，报4.88港元，成交额1715.99万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2303795233","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2303795233?lang=zh_CN&edition=full","pubTime":"2023-01-16 10:40","pubTimestamp":1673836844,"startTime":"0","endTime":"0","summary":"截至2023年1月13日收盘，歌礼制药-B报收于4.63港元，上涨4.04%，换手率0.32%，成交量342.8万股，成交额1561.63万港元。投行对该股的评级以买入为主，近90天内共有1家投行给出买入评级，近90天的目标均价为8.82港元。中信建投证券最新一份研报给予歌礼制药-B买入评级，目标价8.82港元。机构评级详情见下表：歌礼制药-B港股市值50.33亿港元，在生物制品Ⅱ行业中排名第25。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://stock.stockstar.com/RB2023011600001699.shtml","is_publish_highlight":false},{"id":"2303301612","title":"港股异动 | 歌礼制药-B(01672)再涨近6% ASC11多剂量递增I期临床试验完成首个","url":"https://stock-news.laohu8.com/highlight/detail?id=2303301612","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2303301612?lang=zh_CN&edition=full","pubTime":"2023-01-16 10:31","pubTimestamp":1673836310,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘再涨近6%，截至发稿，涨5.4%，报4.88港元，成交额1715.99万港元。　　消息面上，歌礼制药公布，新冠口服蛋白酶抑制剂ASC11联合100 毫克利托那韦片的多剂量递增I期临床试验完成首个队列4名健康受试者给药。　　据悉，在新冠病毒感染的抗病毒细胞实验中，ASC11显示出远高于奈玛特韦、 S-217622、PBI-0451和EDP-235等其他3CLpro抑制剂的抗新冠病毒活性。ASC11 对多种广泛传播的奥密克戎变异株如BA.1和BA.5均保持强效抗病毒活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2023/01/16103137284222.shtml","is_publish_highlight":false},{"id":"2303132793","title":"歌礼制药－Ｂ(01672.HK)新冠口服药完成首个队列4名健康受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2303132793","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2303132793?lang=zh_CN&edition=full","pubTime":"2023-01-16 08:30","pubTimestamp":1673829000,"startTime":"0","endTime":"0","summary":"歌礼制药－Ｂ公布，新冠口服蛋白酶抑制剂ASC11联合100毫克利托那韦片的多剂量递增I期临床试验完成首个队列4名健康受试者给药。该I期临床试验计划入组72名健康受试者，包括单剂量递增和多剂量递增队列60名受试者和食物影响试验12名受试者，入组预计将于今年第一季完成。公司指出，在新冠病毒感染的抗病毒细胞实验中，ASC11显示出远高于奈玛特韦、S-217622、PBI-0451和EDP-235等其他3CLpro抑制剂的抗新冠病毒活性。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239052/latest-news/HK6","is_publish_highlight":false},{"id":"2303547322","title":"歌礼制药-B(01672)宣布新冠口服3CLpro抑制剂ASC11多剂量递增I期临床试验完成首个队列4名健康受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2303547322","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2303547322?lang=zh_CN&edition=full","pubTime":"2023-01-16 08:02","pubTimestamp":1673827352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，新冠口服蛋白酶抑制剂ASC11联合100. 毫克利托那韦片的多剂量递增I期临床试验完成首个队列4名健康受试者给药。该I期临床试验计划入组72名健康受试者，包括单剂量递增和多剂量递增队列60. 名受试者和食物影响试验12名受试者，入组预计将于2023年第一季度完成。在新冠病毒感染动物模型中，ASC11同样表现出强效抗病毒活性。歌礼已在全球范围内递交多项ASC11和相关化合物及其治疗病毒性疾病用途的专利申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/862287.html","is_publish_highlight":false},{"id":"2301613280","title":"歌礼制药-B盘中异动 大幅上涨5.32%报4.950港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2301613280","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2301613280?lang=zh_CN&edition=full","pubTime":"2023-01-05 14:35","pubTimestamp":1672900532,"startTime":"0","endTime":"0","summary":"2023年01月05日下午盘14时35分，歌礼制药-B股票出现波动，股价快速拉升5.32%。截至发稿，该股报4.950港元/股，成交量534.6万股，换手率0.49%，振幅8.72%。机构评级方面，在所有3家参与评级的机构中，67%的券商给予买入建议，33%的券商给予卖出建议，无券商给予持有建议。歌礼制药-B股票所在的生物技术行业中，整体涨幅为2.75%。目前需要治疗的 NASH 患者人群数量庞大，却缺乏有效的治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230105143532834779d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230105143532834779d7&s=b","is_publish_highlight":false},{"id":"2300455736","title":"Viking Therapeutics(VKTX.US)起诉Ascletis Pharma(ASCLF.US)窃取商业机密","url":"https://stock-news.laohu8.com/highlight/detail?id=2300455736","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2300455736?lang=zh_CN&edition=full","pubTime":"2023-01-03 20:34","pubTimestamp":1672749267,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，总部位于圣地亚哥的生物技术公司Viking Therapeutics在加州联邦法院对其中国竞争对手Ascletis Pharma提起诉讼，指控后者窃取了与肝脏疾病药物相关的商业秘密。在向加州南区法院提起的诉讼中，Viking指控Ascletis在2016年和2019年讨论合作时收到了关于其甲状腺激素受体激动剂VK2809的机密信息，这是保密披露协议的一部分。Viking要求赔偿损失，希望法院阻止竞争疗法的开发，并宣布其为商业秘密产生的产品和知识产权的合法所有者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/856619.html","is_publish_highlight":false},{"id":"2300016104","title":"歌礼制药-B(01672.HK)早盘低开逾5%，截至发稿，跌5.27%，报4.49港元，成交额25.59万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2300016104","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2300016104?lang=zh_CN&edition=full","pubTime":"2023-01-03 09:30","pubTimestamp":1672709446,"startTime":"0","endTime":"0","summary":"截至2022年12月30日收盘，歌礼制药-B报收于4.74元，上涨1.94%，换手率0.87%，成交量941.98万股，成交额4574.21万元。投行对该股关注度不高，90天内无投行对其给出评级。歌礼制药-B港股市值51.53亿港元，在生物制品Ⅱ行业中排名第25。主要指标见下表：以上内容由证券之星根据公开信息整理，与本站立场无关。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://stock.stockstar.com/RB2023010300001088.shtml","is_publish_highlight":false},{"id":"2300482160","title":"歌礼制药-B盘中异动 大幅下跌7.15%报4.401港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2300482160","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2300482160?lang=zh_CN&edition=full","pubTime":"2023-01-03 09:30","pubTimestamp":1672709408,"startTime":"0","endTime":"0","summary":"2023年01月03日早盘09时30分，歌礼制药-B股票出现波动，股价急速下挫7.15%。截至发稿，该股报4.401港元/股，成交量13.2万股，换手率0.01%，振幅4.01%。资金方面，该股资金流入16.954万港元，流出20.92万港元。歌礼制药-B股票所在的生物技术行业中，整体跌幅为1.27%。其相关个股中，巨子生物、药明生物、诺诚健华-B涨幅较大，振幅较大的相关个股有荣昌生物-B、诺诚健华-B、康宁杰瑞制药-B，振幅分别为0.00%、0.00%、0.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230103093009846cf7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230103093009846cf7d4&s=b","is_publish_highlight":false},{"id":"2300042471","title":"快讯：生物技术股走低 君实生物跌近9%歌礼制药跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2300042471","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2300042471?lang=zh_CN&edition=full","pubTime":"2023-01-03 09:28","pubTimestamp":1672709320,"startTime":"0","endTime":"0","summary":"1月3日消息，生物技术股走低，君实生物跌近9%，歌礼制药跌超5%，昭衍新药跌近4%，康希诺生物、药明生物跌超2%。\n\n\n炒股开户享福利，入金抽188元红包，100%中奖！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-01-03/doc-imxywncr9089432.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-01-03/doc-imxywncr9089432.shtml","is_publish_highlight":false},{"id":"2300482491","title":"快讯| 恒生指数低开1.07%，生物医药、地产股表现较弱，君实生物跌近9%，歌礼制药跌超5%，龙湖集团跌近4%；科网股多数低开，京东集团跌3.27%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2300482491","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2300482491?lang=zh_CN&edition=full","pubTime":"2023-01-03 09:22","pubTimestamp":1672708969,"startTime":"0","endTime":"0","summary":"恒生指数低开1.07%，生物医药、地产股表现较弱，君实生物跌近9%，歌礼制药跌超5%，龙湖集团跌近4%；科网股多数低开，京东集团跌3.27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301030922498060bb85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301030922498060bb85&s=b","is_publish_highlight":false},{"id":"2300482125","title":"歌礼制药：美国制药公司Viking指控无根据","url":"https://stock-news.laohu8.com/highlight/detail?id=2300482125","media":"老虎证券","top":-1,"share":"https://www.laohu8.com/m/news/2300482125?lang=zh_CN&edition=full","pubTime":"2023-01-02 22:33","pubTimestamp":1672670003,"startTime":"0","endTime":"0","summary":"【歌礼制药：美国制药公司Viking指控无根据】美港电讯APP 1月2日讯，歌礼制药(01672.HK)公布，董事会近日获悉，一家位于美国的制药公司Viking Therapeutics, Inc.就歌礼候选药物ASC41及ASC43F向该公司、其创始人吴劲梓及该公司若干附属公司作出若干控告。根据该等控告所载有关Viking指控的公开资料，歌礼认为该等指控并无根据，并将就该等控告进行有力抗辩。该公司将密切关注上述法律诉讼，而集团的业务及运营一切正常。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301022308178249c7e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301022308178249c7e6&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0251},{"period":"1month","weight":-0.0992},{"period":"3month","weight":0.4775},{"period":"6month","weight":0.2305},{"period":"1year","weight":0.0783},{"period":"ytd","weight":-0.0992}],"websiteUrl":"http://www.ascletis.com","compareEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.1158},{"period":"3month","weight":0.4389},{"period":"6month","weight":0.0926},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.1158}],"name":"歌礼制药-B","description":"歌礼制药有限公司是一家主要从事生物制品研发的中国公司。该公司主要专注于抗病毒、癌症及脂肪肝疾 病三大治疗领域。该公司的主要产品包括抗丙型肝炎病毒（HCV）、人类免疫缺陷病毒（HIV）及乙型肝炎（HBV）药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.094824},{"month":2,"riseRate":0.8,"avgChangeRate":0.050013},{"month":3,"riseRate":0.25,"avgChangeRate":-0.060913},{"month":4,"riseRate":0.5,"avgChangeRate":-0.031475},{"month":5,"riseRate":0.5,"avgChangeRate":0.046574},{"month":6,"riseRate":0.25,"avgChangeRate":-0.007524},{"month":7,"riseRate":0.25,"avgChangeRate":-0.104615},{"month":8,"riseRate":0,"avgChangeRate":-0.102688},{"month":9,"riseRate":0,"avgChangeRate":-0.109833},{"month":10,"riseRate":0.6,"avgChangeRate":-0.074888},{"month":11,"riseRate":0.8,"avgChangeRate":0.17753},{"month":12,"riseRate":0.6,"avgChangeRate":0.041132}],"exchange":"SEHK","nameEN":"ASCLETIS-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.11.11","shortVersion":"4.11.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}